•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Dividend Announcements: October 31-November 6, 2026 (Part 1 Of 2)
California Resources Corporation (CRC) Q3 2026 Earnings Call Transcript
What California Resources (CRC) Said on Its Q3 Earnings Call
Bloom Energy Rallies 11% on Barclays Upgrade and California Resources Tie-Up; FuelCell Energy Gains 5%, GE Vernova Climbs 3%
What's Going On With Bloom Energy Shares Tuesday?
California Resources Corporation (CRC) Q3 Earnings and Revenues Beat Estimates
California Resources Corporation Reports Third Quarter 2026 Financial and Operating Results
Carbon TerraVault Provides Third Quarter 2026 Update
California Resources Corporation Announces Strategic Collaboration with Bloom Energy to Advance Decarbonized Power Across California
Analysts Estimate California Resources Corporation (CRC) to Report a Decline in Earnings: What to Look Out for
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
/C O R R E C T I O N - AbbVie/
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology